Identification of an anergic BND cell-derived activated B cell population (BND2) in young-onset type 1 diabetes patients.
Zachary C StenslandChristopher A MageraHali BroncuciaBrittany D GomezNasha M Rios-GuzmanKristen L WellsCatherine A NicholasMarynette RihanekMaya J HunterKevin P ToolePeter A GottliebJohn C CambierPublished in: The Journal of experimental medicine (2023)
Recent evidence suggests a role for B cells in the pathogenesis of young-onset type 1 diabetes (T1D), wherein rapid progression occurs. However, little is known regarding the specificity, phenotype, and function of B cells in young-onset T1D. We performed a cross-sectional analysis comparing insulin-reactive to tetanus-reactive B cells in the blood of T1D and controls using mass cytometry. Unsupervised clustering revealed the existence of a highly activated B cell subset we term BND2 that falls within the previously defined anergic BND subset. We found a specific increase in the frequency of insulin-reactive BND2 cells in the blood of young-onset T1D donors, which was further enriched in the pancreatic lymph nodes of T1D donors. The frequency of insulin-binding BND2 cells correlated with anti-insulin autoantibody levels. We demonstrate BND2 cells are pre-plasma cells and can likely act as APCs to T cells. These findings identify an antigen-specific B cell subset that may play a role in the rapid progression of young-onset T1D.
Keyphrases
- type diabetes
- induced apoptosis
- glycemic control
- cell cycle arrest
- lymph node
- cardiovascular disease
- middle aged
- signaling pathway
- end stage renal disease
- single cell
- endoplasmic reticulum stress
- chronic kidney disease
- metabolic syndrome
- machine learning
- newly diagnosed
- skeletal muscle
- prognostic factors
- transcription factor
- binding protein
- preterm birth
- patient reported
- sentinel lymph node
- sensitive detection
- locally advanced